Zilovertamab vedotin, an antibody drug conjugate (ADC) developed by Merck & Co (MSD) to treat diffuse large B-cell lymphoma (DLBCL), has demonstrated promise in a Phase II/III study, as the ...

Merck & Co., Inc. (NYSE:MRK) is one of the 15 best stocks to invest in for an 18 year old. On June 10, Cantor Fitzgerald ...

Merck & Co (MSD) has initiated the randomised MOBILIZE-1 Phase III trial to assess the immunogenicity, efficacy, and safety of the investigational quadrivalent vaccine, V181, designed to prevent ...

Benchling announced a new collaboration with Merck, known as MSD outside of the United States and Canada, to implement a ...

RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that Robert M. Davis, chairman and chief executive officer, and Dr. Dean Y.

DURHAM, N.C.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today the opening of a new, $1 billion, 225,000-square-foot facility dedicated to ...

2025--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the initiation of the MOBILIZE-1 Phase 3 clinical trial evaluating the safety, ...

Merck & Co/MSD has won approval in the US for PD-1 inhibitor Keytruda as a treatment for hepatocellular carcinoma (HCC), the most common form of liver cancer, opening up another front in its ...

Currently, Merck stock shows potential for another collar setup, with defined risk and reward, though I haven't executed a ...

RAHWAY, N.J. - Merck & Co., Inc. (NYSE: MRK), a leading global biopharmaceutical company, has announced that its Board of Directors approved a quarterly dividend for the third quarter of 2025 ...

Merck's (NYSE:MRK) top-selling drug – Keytruda's – impressive recent growth tells a compelling story, but it's one with a predictable ending. The pharmaceutical giant's remarkable performance ...